{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T14:33:38Z","timestamp":1778855618271,"version":"3.51.4"},"reference-count":9,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T00:00:00Z","timestamp":1627516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Since all clinical trials conducted during the development of anti-COVID-19 vaccines have adopted among the exclusion criteria the presence of immunodepression or immunomodulating therapy, to date, the effects of vaccination against the new coronavirus 2 in people under such conditions have yet to be clearly defined. The primary objective of the study is to assess the safety of treatment with biotechnological drugs in patients suffering from moderate\u2013severe psoriasis and subjected to the prophylactic vaccination against SARS-Cov-2. Additionally, the secondary objective of the research is to investigate the existence of a possible impact of anti-COVID-19 vaccination on the natural chronic-relapsing course and the severity of the psoriatic disease. The study included 436 patients with moderate\u2013severe psoriasis, both male and female, in treatment with biologics. The data were collected using the direct interview method. A reduction of 74.13% of average Psoriasis Area Severity Index (PASI )compared to baseline (T0) was found in all subjects; this does not differ significantly from the group that underwent vaccination (73.4%). Moreover; at the end of the study, neither mild nor severe adverse events (ADR) were observed among them. In conclusion, biotechnological drugs used in the management of patients with moderate\u2013severe psoriasis demonstrate a high safety profile also in subjects immunized against SARS-Cov-2.<\/jats:p>","DOI":"10.3390\/jcm10153355","type":"journal-article","created":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T10:47:46Z","timestamp":1627555666000},"page":"3355","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Safety and Impact of Anti-COVID-19 Vaccines in Psoriatic Patients Treated with Biologics: A Real Life Experience"],"prefix":"10.3390","volume":"10","author":[{"given":"Nevena","family":"Skroza","sequence":"first","affiliation":[{"name":"Dermatology Unit \u201cD. Innocenzi\u201d, Sapienza University of Rome, Polo Pontino, 04100 Terracina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicoletta","family":"Bernardini","sequence":"additional","affiliation":[{"name":"Dermatology Unit \u201cD. Innocenzi\u201d, Sapienza University of Rome, Polo Pontino, 04100 Terracina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ersilia","family":"Tolino","sequence":"additional","affiliation":[{"name":"Dermatology Unit \u201cD. Innocenzi\u201d, Sapienza University of Rome, Polo Pontino, 04100 Terracina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3795-3190","authenticated-orcid":false,"given":"Ilaria","family":"Proietti","sequence":"additional","affiliation":[{"name":"Dermatology Unit \u201cD. Innocenzi\u201d, Sapienza University of Rome, Polo Pontino, 04100 Terracina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Mambrin","sequence":"additional","affiliation":[{"name":"Dermatology Unit \u201cD. Innocenzi\u201d, Sapienza University of Rome, Polo Pontino, 04100 Terracina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Marchesiello","sequence":"additional","affiliation":[{"name":"Dermatology Unit \u201cD. Innocenzi\u201d, Sapienza University of Rome, Polo Pontino, 04100 Terracina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Marraffa","sequence":"additional","affiliation":[{"name":"Dermatology Unit \u201cD. Innocenzi\u201d, Sapienza University of Rome, Polo Pontino, 04100 Terracina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Rossi","sequence":"additional","affiliation":[{"name":"Dermatology Unit \u201cD. Innocenzi\u201d, Sapienza University of Rome, Polo Pontino, 04100 Terracina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Volpe","sequence":"additional","affiliation":[{"name":"Dermatology Unit \u201cD. Innocenzi\u201d, Sapienza University of Rome, Polo Pontino, 04100 Terracina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Concetta","family":"Potenza","sequence":"additional","affiliation":[{"name":"Dermatology Unit \u201cD. Innocenzi\u201d, Sapienza University of Rome, Polo Pontino, 04100 Terracina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"ref_3","unstructured":"International Psoriasis Council (2021, July 28). IPC Statement on SARS-COV-2 Vaccines and Psoriasis. Available online: https:\/\/www.psoriasiscouncil.org\/blog\/IPC-Statement-on-SARS-CoV-2-Vaccines-and-Psoriasis.htm."},{"key":"ref_4","unstructured":"(2021, July 28). NPF COVID-19 Task Force Issues New Guidance Statements Regarding COVID-19 Vaccines along with Updates to Prior Guidance. Available online: https:\/\/www.dermatologytimes.com\/view\/npf-covid-19-task-force-issues-updated-guidance-statements."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(20)30763-7","article-title":"Ensuring global access to COVID-19 vaccines","volume":"395","author":"Yamey","year":"2020","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jaad.2020.12.058","article-title":"National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the Pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments","volume":"84","author":"Gelfand","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"9318","DOI":"10.1128\/JVI.01049-10","article-title":"T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus- infected mice","volume":"84","author":"Zhao","year":"2010","journal-title":"J. Virol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2020.07.026","article-title":"Acute SARS-CoV-2 infection impairs dendritic cell and T cell responses","volume":"53","author":"Zhou","year":"2020","journal-title":"Immunity"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41577-020-00434-6","article-title":"Immunological considerations for COVID-19 vaccine strategies","volume":"20","author":"Jeyanathan","year":"2020","journal-title":"Nat. Rev. Immunol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/15\/3355\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:36:42Z","timestamp":1760164602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/15\/3355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,29]]},"references-count":9,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["jcm10153355"],"URL":"https:\/\/doi.org\/10.3390\/jcm10153355","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,29]]}}}